<DOC>
	<DOCNO>NCT00612196</DOCNO>
	<brief_summary>Dose escalation study assess safety tolerability TB-402 , monoclonal antibody direct FVIII , versus placebo healthy male volunteer .</brief_summary>
	<brief_title>A Phase I Study Monoclonal Antibody TB-402 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<criteria>Males 18 45 ( Groups 19 ) 55 75 ( Group 10 ) year age No clinically important abnormal physical , laboratory , ECG finding Normal ( abnormal nc ) supine blood pressure ( BP ) heart rate ( HR ) Self family history cardiovascular pulmonary disorder , coagulation bleed disorder reasonable suspicion vascular malformation eg cerebral haemorrhage , aneurysm premature stroke . Any autoimmune disease . Previous allergic reaction immunoglobulin . Present , history , severe allergy , example asthma anaphylactic reaction allergy require treatment . Consumption aspirin , nonsteroidal antiinflammatory drug drug know affect platelet function aspect coagulation within 14 day drug administration . Abnormal platelet function clinically significant range value coagulation test . History important bleeding episode eg haematemesis , rectal bleeding , severe recurrent epistaxis , haemoptysis , haematuria intracranial haemorrhage . Screening FVIII : C &lt; 50 % .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Safety tolerability</keyword>
</DOC>